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Summary 
Background: The aim of this study was to compare serum
sclerostin concentrations in patients with thyroid dysfunc-
tion with euthyroid control subjects and to assess the rela-
tionship between sclerostin and markers of bone metabo-
lism (osteocalcin and beta-cross-laps).
Methods: The study included 30 patients with thyroid dys-
function (hypothyroidism, hyperthyroidism and subclinical
hyperthyroidism) and ten euthyroid controls. Free thyroxine
(FT4) was measured by radioimmunoassay, while thyroid
stimulating hormone (TSH) concentration was determined
immunoradiometrically. We used an ELISA kit to determine
the sclerostin level. The electrochemiluminescence method
was applied for measuring the bone markers.
Results: Sclerostin levels were significantly lower in hypothy-
roid patients (p=0.009) and significantly elevated in hyper-
thyroid patients (p=0.008) compared to control values.
Hyperthyroid patients also had higher sclerostin than
patients with subclinical hyperthyroidism (p=0.013).
Sclerostin concentrations were negatively correlated with
TSH levels (r=-0.746, p<0.001), but positively with FT4
(r=0.696, p < 0.001). Moreover, sclerostin was positively
associated with osteocalcin (r=0.605, p=0.005) and beta-
Kratak sadr`aj
Uvod: Cilj ove studije bio je da uporedimo serumske koncen-
tracije sklerostina kod pacijenata sa disfunkcijom {ti taste
`lezde u odnosu na eutiroidne kontrolne ispitanike, i da pro -
cenimo odnos izme|u sklerostina i markera ko{tanog meta -
bolizma (osteokalcina i beta-cross-lapsa) u istoj populaciji.
Metode: Studijom je obuhva}eno 30 pacijenata sa disfunk -
cijom {titaste `lezde (hipotireozom, hipertireozom i subkli-
ni~kom hipertireozom) i 10 eutiroidnih kontrola. Slobodni
tiroksin (FT4) meren je radioimunolo{kom metodom, dok
je koncentracija tireostimuli{u}eg hormona (TSH) odre |i -
vana imunoradiometrijski. Za merenje nivoa sklerostina
koristili smo ELISA-test. Metoda elektrohemiluminiscencije
primenjena je za merenje koncentracije ko{tanih markera.
Rezultati: Nivo sklerostina bio je zna~ajno ni`i kod bolesni-
ka sa hipotireozom (p = 0,009) odnosno zna~ajno vi{i kod
bolesnika sa hipertireozom (p = 0,008) u pore|enju sa
vrednostima kod eutiroidnih kontrolnih ispitanika. Pacijenti
sa hipertireozom su tako|e imali statisti~ki zna~ajno vi{i
nivo sklerostina u odnosu na bolesnike sa subklini~kom
hiper tireozom (p = 0,013). Pokazana je negativna kore -
lacija koncentracije sklerostina i TSH (r = -0,746, p <
0,001), odnosno pozitivna korelacija sa FT4 (r = 0,696, p
List of abbreviations: DTC, differentiated thyroid carcinoma;
GD, Graves’ disease; HT, Hashimoto’s thyroiditis
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Introduction
Bone homeostasis is based on the balance
between two coupled processes: bone resorption and
bone formation, so any removed damaged bone must
be replaced by an equal amount of healthy tissue (1).
There are many influences involved in bone home-
ostasis, such as genetic factors, growth factors,
mechanical load, hormonal and metabolic status. 
Thyroid hormones are known to play a key role
in the regulation of metabolism and development of
different organs, including bones. They are necessary
for the maintenance of bone structure and strength
and the achievement of peak bone mass (2). Thyroid
hormones have been shown to change the duration
of the bone remodelling cycle and to alter relations
between bone formation and bone resorption (3).
During bone growth, thyroid hormones have mainly
anabolic effects, while they predominantly exert cata-
bolic action in adults (4).
Thyroid-stimulating hormone (TSH) can also
influence skeletal development, as the expression of
TSH receptors has been demonstrated in both
osteoblasts and osteoclasts (5, 6). It may have a
direct effect on bone tissue by inhibition of osteoclas-
togenesis (7). Certainly bone homeostasis is influ-
enced by the balanced actions of thyroid hormones
and TSH (5).
Sclerostin is an osteocyte-derived protein,
encoded by the SOST gene. This regulator of skeletal
metabolism acts as an inhibitor of bone formation (8)
by stimulating apoptosis of osteocytes and osteoblasts
(9). Sclerostin also reduces bone mineral content and
cortical thickness, and thus makes bones less resist-
ant (10). Previous studies indicated that serum scle-
rostin is negatively correlated with parathormone and
cortisol but positively correlated with calcitonin (11–
13). However, published data on the relationship
between sclerostin and thyroid hormones are scarce
and mostly relate to findings obtained in animal stud-
ies (14, 15).
In humans, sclerostin has been analyzed in
hyperthyroid patients before and during antithyroid
therapy (10, 16). The cross-sectional study of Engler
et al. (17) established significant correlations
between thyroid hormone excess and faster bone
turnover, observed through an increase of bone
degradation markers in overt hyperthyroidism.
Regarding patients with subclinical hyperthyroidism,
various studies have indicated either normal or elevat-
ed bone resorption markers (18, 19). 
Likewise, available results about sclerostin and
markers of bone metabolism also diverge. Some
authors demonstrated that sclerostin correlates nega-
tively with both markers of bone formation and bone
resorption, while others affirmed a positive correlation
only with bone resorption markers (20–22).
This study aimed to compare serum concentra-
tions of sclerostin in patients with abnormal thyroid
function (hypothyroidism, hyperthyroidism and sub-
clinical hyperthyroidism) with values for healthy euthy-
roid individuals. Possible mutual relationships of
serum sclerostin levels and thyroid status, and both
sclerostin and thyroid status with bone metabolism
markers (osteocalcin and b-cross-laps) were analyzed
in all study subjects. 
Materials and Methods
Study population
The study population included 30 patients with
thyroid dysfunction: 23 (79.3%) females and 7
(20.7%) males of mean age 48.31±18.23 yrs.
Patients with thyroid gland disorders were divided into
three groups: 10 patients with hypothyroidism due to
Hashimoto’s thyroiditis (HT), 10 patients with hyper-
thyroidism due to Graves’ disease (GD) and 10
patients with subclinical hyperthyroidism due to thy-
roxine suppressive therapy (differentiated thyroid car-
cinoma, DTC). Hashimoto’s thyroiditis and Graves’
disease were diagnosed based on clinical pre senta -
tion, high levels of antithyroid antibodies (561.94±
1022.1 U/mL for TgAbs and 5523±4070 U/mL
for TPOAbs in HT and 18.47±18.14 U/mL for
TSHRAbs in GD) and TSH concentrations. DTC was
diagnosed histologically, according to the main prin-
ciples of the current WHO classification of thyroid
tumours (23). All DTC patients included in this study
had undergone total thyroidectomy and were then
treated with fixed nominal activities of sodium (131-I)
cross-laps levels (r=0.573, p=0.008) in all thyroid
patients.
Conclusions: Serum sclerostin is significantly affected in
subjects with thyroid dysfunction. Both sclerostin and thy-
roid status affect bone homeostasis, which is reflected
through the significant correlations with osteocalcin and
beta-cross-laps.
Keywords: beta-cross-laps, bone metabolism, osteocal-
cin, sclerostin, thyroid dysfunction
< 0,001) kod pacijenata sa tireoidnom disfunkcijom.
[tavi{e, sklerostin pozitivno korelira sa koncentarcijom
osteokalcina (r = 0,605, p = 0,005) i beta-cross-lapsa (r
= 0,573, p = 0,008) kod ovih pacijenata. 
Zaklju~ak: Serumski nivoi sklerostina izmenjeni su kod
osoba sa disfunkcijom {titaste `lezde. Sklerostin zajedno sa
tireoidnim statusom uti~e na ko{tani metabolizam, {to se
ogleda u njegovoj zna~ajnoj korelaciji sa osteokalcinom i
beta-cross-lapsom.
Klju~ne re~i: beta-cross-laps, ko{tani metabolizam,
osteokalcin, sklerostin, tireoidna disfunkcija
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iodide administered orally according to the EANM
guidelines (24). In all DTC patients, subsequent
whole-body scintigraphy detected no regional or dis-
tant metastases. 
The control group comprised 10 healthy sub-
jects, 9 (90%) females and 1 (10%) male of mean
age 46.5±10.23 yrs. All control subjects were evalu-
ated for thyroid function and absence of thyroid anti-
bodies. 
None of the study participants had acute infec-
tions or other conditions that could affect the tested
parameters. After venipuncture, blood samples (5
mL) from patients and control subjects were collected
in tubes (Vacutainer) without anticoagulants.
Approximately 30 min after venipuncture, serum
samples were obtained by centrifugation at 2000 rpm
for 15 min and frozen at - 20 °C until required for bio-
chemical analysis. 
The study was planned according to ethical
guidelines following the Declaration of Helsinki. The
institutional review committee of Clinical Center
Kragujevac approved our study protocol according to
local biomedical research regulations. All patients
and control subjects gave informed consent prior to
enrolment in the investigation.
Measurement of free thyroxine (fT4) and thy-
roid-stimulating hormone (TSH)
Free thyroxine (fT4) concentration was meas-
ured by radioimmunoassay (RIA, OCFD03-FT4, Cis-
Biointernational, France), with a reference range of
7–18 pg/mL. Thyroid-stimulating hormone (TSH)
concentration was determined immunoradiometrical-
ly (IRMA TSH, INEP, Zemun, Serbia), with a reference
range of 0.3–5.5 mU/L. All measurements were
made on a Wallac Wizard 1470 Automatic gamma
counter (PerkinElmer Life Sciences, WallacOy, 2005,
Finland).
Measurement of serum sclerostin
Serum sclerostin was determined by quantitative
sandwich enzyme immunoassay (DSST00 Human
SOST Immunoassay, R&D Systems, USA). A mono-
clonal antibody specific for human sclerostin was pre-
coated onto a microplate. Aliquots of standards and
samples were pipetted into the wells for any sclerostin
present to be bound by the immobilized antibody.
After washing away all unbound substances, an
enzyme-linked polyclonal antibody specific for human
sclerostin was added to the wells. Following a wash to
remove any unbound antibody-enzyme reagent, sub-
strate solution was added for colour to develop in pro-
portion to the amount of sclerostin bound in the initial
step. After stopping further development, the colour
intensity was measured at 540 nm. Intraassay and
interassay coefficients of variance (CV) were 2% and
9.5%, respectively.
Determination of serum osteocalcin and b-cross-
laps
Serum osteocalcin and b-cros-laps were meas-
ured by electrochemiluminescence on a Cobas e 411
analyzer (Roche Diagnostics). The reference range for
osteocalcin and b-cross-laps were 11–43 ng/mL and
0.010–5.940 ng/mL, respectively.  
Statistical analysis 
All values were expressed as mean ± standard
deviation (SD). The commercial SPSS version 13.0
for Windows was used for statistical analysis. The sig-
nificance of differences in the determined parameters
between various groups was analyzed by the
Independent samples t-test or Mann-Whitney U-test
(depending on the distribution). Association between
variables was evaluated by the bivariate correlation
test and Pearson/Spearman coefficient. Chi-square
tests were used to evaluate categorical data.
Probability (p) values less than 0.05 were considered
to be statistically significant. 
Results
We determined sclerostin concentrations in sera
samples from groups of patients with thyroid dysfunc-
tion (hypothyroidism, hyperthyroidism and subclinical
hyperthyroidism) and compared them with each other
and with those for control subjects. Also, we analyzed
the relationships of circulating serum sclerostin levels
with osteocalcin and b-cross-laps concentrations.
There were no significant differences in age or
gender distribution among the patients subgroups
and control group (hypothyroid group: c2=18.0,
p=0.324 for age and c2=1.25, p=0.264 for gender;
hyperthyroid group: c2=12.98, p=0.449 for age and
c2=1.25, p=0.264 for gender; sub-hyperthyroid
group: c2=15.33, p=0.356 for age and c2=1.05,
p=0.305 for gender). 
Peripheral serum concentrations of sclerostin,
free thyroxine and thyroid-stimulating hormone in our
study groups are given in Table I, mean serum scle-
rostin, osteocalcin and b-cross-laps concentrations
are shown in Figure 1 (A, B, C). There were signifi-
cant differences in the levels of serum sclerostin
(Kruskal-Wallis test, p<0.001), osteocalcin (One way
ANOVA, p=0.014) and beta-cross-laps (One way
ANOVA, p<0.001) between the study groups. We
found that patients with hypothyroidism had much
lower serum sclerostin concentrations than control
subjects (66.54±48.13 pg/mL vs 145.91±81.36
pg/mL) (Mann Whitney test, p=0.009). In contrast,
concentrations of sclerostin were significantly higher
J Med Biochem 2020; 39 (4) 439
Figure 1 Differences in serum sclerostin (A), osteocalcin (B) and beta-cross-laps (C) concentrations between thyroid patients and
control subjects.
Table I Concentrations (geometric mean) of sclerostin, fT4 and TSH in the study groups.
The values in parentheses represent the 95% confidence interval of geometric mean, and the differences were considered statis-
tically different if p-value was < 0.05.
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in patients with hyperthyroidism than in control sub-
jects (377.49±197.44 pg/mL vs 145.91±81.36
pg/mL) (Independent samples t-test, p=0.008) and
patients with subclinical hyperthyroidism (Mann
Whitney test, p=0.013). Hyperthyroid patients had
higher concentrations of osteocalcin and beta-cross-
laps in relation to patients with hypothyroidism
(p=0.018 for osteocalcin; p=0.030 for beta-cross-
laps), patients with subclinical hyperthyroidism
(p=0.044 for osteocalcin; p=0.005 for beta-cross-
laps) and control subjects (p=0.034 for osteocalcin;
p=0.041 for beta-cross-laps).
Analysis of the relationship between sclerostin
and FT4 showed a strong positive correlation of scle-
rostin concentrations and free thyroxine in the sub-
jects with thyroid dysfunctions (Bivariate correlation
test, Spearman r=0.696, p<0.001) (Figure 2A). On
the contrary, serum sclerostin was negatively correlat-
ed with TSH in the same participants (Bivariate corre-
lation test, Spearman r=-0.746, p<0.001) (Figure
2B). In the group of control subjects, the correlations
of sclerostin and parameters of thyroid status tended
in the same directions as for the patients, i.e. positive
with FT4 and negative with TSH, but did not reach
the level of statistical significance (rTSH=-0.490,
pTSH=0.150; rFT4=0.382, pFT4=0.386).
When considering the relationship of bone
turnover markers and thyroid status, statistical analy-
sis showed that osteocalcin and beta-cross-laps posi-
tively correlated with FT4 (Spearman r = 0.641, p =
0.003 for osteocalcin; Spearman r=0.522, p=0.022
for beta-cross-laps) but negatively correlated with
TSH (Spearman r =-0.735, p<0.001 for osteocalcin;
Spearman r =-0.612, p=0.004 for beta-cross-laps)
in the patients with altered thyroid function. 
Finally, sclerostin concentrations were positively
associated with both markers of bone metabolism
(osteocalcin and beta-cross-laps) in the patients with
abnormal thyroid function (Spearman r=0.605,
p=0.005 for osteocalcin; Spearman r=0.573,
p=0.008 for beta-cross-laps). The relationship
between serum sclerostin and osteocalcin (Spearman
r=0.131, p=0.779) as well as sclerostin and beta-
cross-laps (Spearman r=0.337, p=0.459) in control
subjects was not statistically significant probably due
to the small number of subjects (n=10) in this group. 
Figure 2 The relationship of sclerostin level with free thyroxine (A) and thyroid-stimulating hormone (B) in subjects with thyroid
dysfunctions.
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Discussion
The aim of our study was to evaluate sclerostin
concentrations in patients with abnormal thyroid
functions (hypothyroidism, hyperthyroidism and sub-
clinical hyperthyroidism) and healthy euthyroid sub-
jects, as well as to analyze the relationship between
sclerostin concentrations and markers of bone metab-
olism (osteocalcin and beta-cross-laps). 
Thyroid hormones are considered important
regulators of bone metabolism, so any deficiency or
excess may result in disturbance of bone turnover.
Current knowledge about the action of thyroid hor-
mones on the skeleton has mainly been obtained
from animal models (5). Since bone remodelling
determines skeletal integrity, thyroid hormones might
change the rate of bone turnover (leading to an accel-
eration in hyperthyroidism or deceleration in hypothy-
roidism) and bone density (3). On the other hand, it
is accepted that TSH can suppress osteoclast forma-
tion and stimulate osteoblast differentiation (6). Abe
and coworkers (5) hypothesized that TSH, rather than
thyroxine and triiodothyronine, is a direct negative
regulator of skeletal development. It seems that skele-
ton maintenance is set by the concerted activity of
thyroid hormones and TSH.
Sclerostin is a glycoprotein product of the SOST
gene expressed mainly in osteocytes (8). It has a neg-
ative effect on bone mineralization because it reduces
bone mineral content and has been the subject of
many studies. Thus, increased serum sclerostin levels
were found in patients with chronic kidney disease
(25), diabetes mellitus (26), prostate cancer (27),
liver dysfunction (28) and obesity (29). Its expression
is regulated mostly by mechanical load, although
many data indicate the great importance of humoral
factors (10, 12, 13). Thus, thyroid hormones were
demonstrated to increase the number of sclerostin-
positive osteocytes in hyperthyroid mice (14, 15).
Here we attempted to clarify the relationship of scle-
rostin and thyroid hormones in humans and are the
first to show differences in circulating sclerostin con-
centrations in patients with three different types of
thyroid dysfunction (hypothyroidism, hyperthyroidism
and subclinical hyperthyroidism).
In earlier studies on sclerostin concentrations in
subjects with hyperthyroidism before and/or after
medicament therapy, Skowrońska-Jóźwiak et al. (10)
and Sarıtekin et al. (16) found no statistically signifi-
cant correlation with thyroid status. Unlike them, we
have compared serum sclerostin concentrations in
patients with different abnormalities of thyroid func-
tion both between the groups of patients and with
healthy euthyroid individuals.
We showed that serum sclerostin concentrations
were the highest in the group of hyperthyroid
patients, significantly higher than in control subjects.
On the contrary, patients with hypothyroidism had
lower serum concentrations of sclerostin than the
other groups. These results are in line with data
obtained by Tsourdi et al. (15) in male mice. It seems
that hypothyroidism, although this may not be expect-
ed, affects bone homeostasis and reduces skeletal
turnover.
Our study also included DTC patients with sub-
clinical hyperthyroidism caused iatrogenically by thy-
roxine suppressive therapy. Subclinical hyperthy-
roidism is characterized by circulating TSH levels
below the reference range and normal serum con-
centrations of thyroid hormones. The small difference
in sclerostin levels between these patients and control
subjects was not statistically significant, although the
mean concentration was slightly higher in patients
with subclinical hyperthyroidism. These results are in
agreement with those of Lee et al. (30), who conclud-
ed that TSH suppression in DTC patients has no
effect on bone health, so suppressive levothyroxine
therapy could be rated safe.
A close positive correlation of sclerostin concen-
trations with thyroxine and a strong negative correla-
tion with TSH in sera samples from our three groups
of patients were observed. The same correlation
trend of sclerostin and thyroid status (FT4 and TSH)
was seen in control subjects but did not reach statis-
tical significance, probably due to the small number
of subjects in the control group.    
Analysis of the relationship with bone metabolic
markers showed that serum sclerostin was positively
associated with osteocalcin and beta-cross-laps levels
in patients with thyroid dysfunctions. Moreover, osteo-
calcin and beta-cross-laps were positively associated
with concentrations of FT4 and negatively with TSH
in all patients. 
Osteocalcin is the most common non-collage-
nous protein of the bone extracellular matrix.
Synthesized by mature osteoblasts (31), it is con -
sidered a marker of bone formation. Thus, serum
osteocalcin level correlates with osteoblast activity,
although fragments can be released into the blood
during bone resorption. In contrast, beta-cross-laps is
a collagen-degradation product and a marker of bone
resorption (32).
In an analysis of osteocalcin concentrations in
patients with abnormal thyroid function (hyperthy-
roidism, hypothyroidism and subacute thyroiditis),
Kojima et al. (33) found a positive correlation with
thyroxine and triiodothyronine levels, suggesting that
osteoblast activity was increased in hyperthyroidism
and decreased in hypothyroidism. Moreover, thyroid
suppressive therapy significantly reduced osteocalcin
concentrations in subjects with hyperthyroidism (34).
Our results correspond with these findings, but we
have also demonstrated that both osteocalcin and
beta-cross-laps are associated with thyroid status in
patients with different thyroid dysfunctions. Further -
more, we have examined the relationship of sclerostin
with other bone metabolism markers, which was not
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the subject of previous research. Earlier results about
the association of sclerostin and markers of bone
metabolism mostly concerned a healthy elderly popu-
lation or immobilized subjects. Thus some authors
demonstrated that sclerostin correlates negatively
with markers of bone formation and bone resorption,
while others affirmed a positive correlation only with
bone resorption markers (20–22). Unlike Sarıtekin et
al. (16), our examination indicated positive relation-
ships of serum sclerostin with both osteocalcin and
beta-cross-laps in patients with abnormal thyroid
function. The differences in sclerostin concentration
in our study participants reflect changes in the level of
osteocalcin and beta-cross-laps and vice versa. As a
marker of bone formation, osteocalcin showed the
same distribution among our study groups as scle-
rostin and beta-cross-laps (the highest values in
hyperthyroid patients, the lowest in hypothyroid
patients). We assume that is a consequence of a com-
pensatory reaction (as increased osteoblast activity) in
the case of disturbed bone balance. This has been
shown in some other conditions, e.g. in subjects with
Wilson’s disease and postmenopausal females (35,
36).
Study limitations
The principal limitation of our study is the rela-
tively small samples size. Secondly, wide confidence
intervals of the selected associations indicate a limited
statistical strength. Thus, further examinations are
needed in order to verify the strength of the observed
associations.
In conclusion, serum concentrations of scle-
rostin are significantly affected in subjects with differ-
ent abnormal thyroid functions. Thus, patients with
hyperthyroidism had the highest level of sclerostin
and patients with hypothyroidism the lowest. There
were positive relationships between circulating con-
centrations of sclerostin and markers of bone metab-
olism, i.e. osteocalcin a marker of bone formation
and beta-cross-laps marker of bone resorption in all
thyroid patients. Thyroid status affects bone home-
ostasis which is reflected through its significant asso-
ciation with osteocalcin and beta-cross-laps but even
more closely with sclerostin. 
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